Unknown

Dataset Information

0

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN.


ABSTRACT: In SERAPHIN, a long-term, randomised, controlled trial (NCT00660179) in pulmonary arterial hypertension (PAH), macitentan significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation. We evaluated disease progression and the effect of macitentan in treatment-naïve incident and prevalent cohorts.Patients allocated to placebo, or macitentan 3?mg or 10?mg were classified by time from diagnosis to enrolment as incident (?6?months; n=110) or prevalent (>6?months; n=157). The risk of morbidity/mortality and PAH-related death/hospitalisation was determined using Cox regression.The risk of morbidity/mortality (Kaplan-Meier estimates at month 12: 54.4% versus 26.7%; p=0.006) and PAH-related death/hospitalisation (Kaplan-Meier estimates at month 12: 47.3% versus 19.9%; p=0.006) were significantly higher for incident versus prevalent patients receiving placebo, respectively. There was no significant difference in the risk of all-cause death between incident and prevalent cohorts (p=0.587). Macitentan 10?mg significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation versus placebo in incident and prevalent cohorts.Incident patients had a higher risk for PAH progression compared with prevalent patients but not a higher risk of death. Macitentan delayed disease progression in both incident and prevalent PAH patients.

SUBMITTER: Simonneau G 

PROVIDER: S-EPMC4664609 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


In SERAPHIN, a long-term, randomised, controlled trial (NCT00660179) in pulmonary arterial hypertension (PAH), macitentan significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation. We evaluated disease progression and the effect of macitentan in treatment-naïve incident and prevalent cohorts.Patients allocated to placebo, or macitentan 3 mg or 10 mg were classified by time from diagnosis to enrolment as incident (≤6 months; n=110) or prevalent (>6 months; n=157)  ...[more]

Similar Datasets

| S-EPMC5772137 | biostudies-literature
| S-EPMC9402487 | biostudies-literature
2003-11-15 | GSE703 | GEO
| S-EPMC5873992 | biostudies-literature
| S-EPMC9402744 | biostudies-literature
2014-11-14 | E-GEOD-53408 | biostudies-arrayexpress
2020-09-07 | PXD015896 | Pride
| S-EPMC7758287 | biostudies-literature
2016-07-15 | E-GEOD-84395 | biostudies-arrayexpress
2021-06-01 | E-MTAB-10425 | biostudies-arrayexpress